Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high.

We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.

Learn how Portugal’s biotech and life sciences ecosystem is advancing research, startups, and innovation even amid funding ...

Over the past months, GSK has been particularly active on the deal front, expanding its pipeline through multiple moves. In December alone, the company signed a string of partnerships spanning ...

Bristol Myers Squibb is experiencing what many would describe as a pivotal moment as it attempts to balance the strength of its established portfolio with the growing pressure of upcoming patent ...

Brain disorders, neurological and mental health conditions, are on the rise, with a 65% spike in prevalence over the past three decades. Challenging health systems, the burden is expected to increase, ...

Candel Therapeutics is focused on the development of off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight ...

After several years of slowdown, early signs in 2026 suggest that the biotech initial public offering (IPO) market may be reopening. The sector has experienced a prolonged drought, with just 11 ...